ECSP18023544A - Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona - Google Patents

Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona

Info

Publication number
ECSP18023544A
ECSP18023544A ECIEPI201823544A ECPI201823544A ECSP18023544A EC SP18023544 A ECSP18023544 A EC SP18023544A EC IEPI201823544 A ECIEPI201823544 A EC IEPI201823544A EC PI201823544 A ECPI201823544 A EC PI201823544A EC SP18023544 A ECSP18023544 A EC SP18023544A
Authority
EC
Ecuador
Prior art keywords
quinazolin
oxo
amino
methyl
diona
Prior art date
Application number
ECIEPI201823544A
Other languages
English (en)
Inventor
Colin Walters
Xiaoxuan Shen
Jay Brumfield
Indrajit Ghosh
William Bowen
Yali Sun
Daozhong Zou
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of ECSP18023544A publication Critical patent/ECSP18023544A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)

Abstract

Se proveen en la presente las composiciones farmacéuticas y formas de dosificación unitarias de Compuesto A (3-(5-amino-2-metil-4-oxo-4H-quinazolin-3-il)-piperidin-2,6-diona), o un enantiómero o una mezcla de enantiómeros de este, un solvato, hidrato, cocristal, clatrato, polimorfo o sal farmacéuticamente aceptable de este. También se proveen métodos para tratar, controlar o prevenir el cáncer con las formas de dosificación descritas en la presente.
ECIEPI201823544A 2015-08-27 2018-03-27 Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona ECSP18023544A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562210923P 2015-08-27 2015-08-27

Publications (1)

Publication Number Publication Date
ECSP18023544A true ECSP18023544A (es) 2018-04-30

Family

ID=56883865

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201823544A ECSP18023544A (es) 2015-08-27 2018-03-27 Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona

Country Status (17)

Country Link
US (1) US10064863B2 (es)
EP (1) EP3340969B1 (es)
JP (1) JP2018525422A (es)
KR (1) KR20180039084A (es)
CN (1) CN107921004A (es)
AU (1) AU2016310340A1 (es)
BR (1) BR112018003335A2 (es)
CA (1) CA2996641A1 (es)
CL (1) CL2018000489A1 (es)
CO (1) CO2018002545A2 (es)
EA (1) EA201890585A1 (es)
EC (1) ECSP18023544A (es)
ES (1) ES2865289T3 (es)
HK (1) HK1252415A1 (es)
IL (1) IL257666A (es)
MX (1) MX2018002487A (es)
WO (1) WO2017035443A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3316888A1 (en) 2015-07-02 2018-05-09 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
SG11201804367PA (en) 2015-12-02 2018-06-28 Celgene Corp Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
BR112022007468A2 (pt) * 2019-10-21 2022-07-12 Celgene Corp Composições farmacêuticas compreendendo (s)-2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)isoindolina-1,3-diona e métodos para usar as mesmas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
ME02890B (me) 2006-09-26 2018-04-20 Celgene Corp Derivati 5-supstituisanog hinazolinona kao antikancer agensi
TWI601722B (zh) * 2011-03-11 2017-10-11 西建公司 ３-（５-胺基-２-甲基-４-氧基-４ｈ-喹唑啉-３-基）-六氫吡啶-２，６-二酮之固體型式及其醫藥組合物及用途
KR20140019364A (ko) * 2011-03-11 2014-02-14 셀진 코포레이션 면역-관련 및 염증성 질환의 치료에 있어서의 3-(5-아미노-2-메틸-4-옥소퀴나졸린-3(4ｈ)-일)피페리딘-2-6-디온의 용도
US20150196562A1 (en) * 2014-01-15 2015-07-16 Celgene Corporation Formulations of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione

Also Published As

Publication number Publication date
EP3340969B1 (en) 2021-02-17
CA2996641A1 (en) 2017-03-02
BR112018003335A2 (pt) 2018-09-25
IL257666A (en) 2018-04-30
US20170056323A1 (en) 2017-03-02
HK1252415A1 (zh) 2019-05-24
EA201890585A1 (ru) 2018-11-30
CL2018000489A1 (es) 2018-08-03
EP3340969A1 (en) 2018-07-04
CO2018002545A2 (es) 2018-07-10
US10064863B2 (en) 2018-09-04
JP2018525422A (ja) 2018-09-06
ES2865289T3 (es) 2021-10-15
KR20180039084A (ko) 2018-04-17
AU2016310340A1 (en) 2018-03-15
CN107921004A (zh) 2018-04-17
WO2017035443A1 (en) 2017-03-02
MX2018002487A (es) 2018-06-15

Similar Documents

Publication Publication Date Title
CY1124669T1 (el) ΑΝΤΙ-ΟΙΣΤΡΟΓΟΝΙΚΑ ΦΑΡΜΑΚΑ ΤΕΤΡΑΫΔΡΟ-1Η-ΠΥΡΙΔΟ[3,4-b]INΔOΛIOY
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
CO2018008305A2 (es) Formulaciones de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
TN2017000075A1 (en) Compounds and compositions as raf kinase inhibitors
CY1121746T1 (el) Αναστολεις mgat2 τετραζολονο-υποκατεστημενης διυδροπυριδινονης
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
AR100663A1 (es) Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona
MX2021005207A (es) Formulaciones de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-met ilciclohexilamino)-pirimidina-5-carboxamida.
EA201692265A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
UY36123A (es) Derivados de carboxamida
EA201891682A1 (ru) Производное азациклического амида, способ его получения и фармацевтическое применение
ECSP18023544A (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
MX2019010108A (es) Derivados de azetidina.
MX2018015990A (es) Compuestos terapeuticos.
MX2018010652A (es) Composiciones farmaceuticas.
CU20160170A7 (es) Derivados de carboxamida
AR105923A1 (es) Compuestos terapéuticos para el dolor y síntesis de estos